Chehadeh W, Albaksami O, John S E, Al-Nakib W
Acta Virol. 2018;62(3):259-265. doi: 10.4149/av_2018_219.
The identification of human immunodeficiency virus (HIV) mutations leading to drug resistance enables patient-specific adaptation of the treatment regimen and predicts the risk of transmission of drug-resistant HIV. In this study, we report for the first time the prevalence in Kuwait of non-polymorphic resistance-associated mutations (RAMs) in patients under first-line antiretroviral therapy. Viral RNA was extracted from plasma samples of 64 treatment-naïve (untreated) and 64 treatment-experienced patients. The HIV-1 load was determined by real-time RT-PCR. The protease- and reverse transcriptase-encoding regions were analyzed by subtyping, and for drug resistance. The HIV-1 load at sampling in treatment-naïve patients ranged from 1.61 x 104 to 1.91 x 106 copies/ml, whereas that in treatment-experienced patients ranged from bitors (PIs) and NNRTIs. These results necessitate efforts to be made for reducing emergence of resistance-associated mutations in treated patients, and highlight the need for continuous monitoring of drug resistance patterns in Kuwait.
鉴定导致耐药性的人类免疫缺陷病毒（HIV）突变，有助于根据患者具体情况调整治疗方案，并预测耐药性HIV传播的风险。在本研究中，我们首次报告了科威特接受一线抗逆转录病毒治疗患者中与耐药相关的非多态性突变（RAMs）的流行情况。从64例初治（未治疗）患者和64例经治患者的血浆样本中提取病毒RNA。通过实时逆转录聚合酶链反应（RT-PCR）测定HIV-1载量。通过基因分型分析蛋白酶和逆转录酶编码区，并检测耐药性。初治患者采样时的HIV-1载量范围为1.61×10⁴至1.91×10⁶拷贝/毫升，而经治患者的HIV-1载量范围为双肽酶抑制剂（PIs）和非核苷类逆转录酶抑制剂（NNRTIs）。这些结果表明需要努力减少接受治疗患者中耐药相关突变的出现，并强调在科威特持续监测耐药模式的必要性。
